Fate Therapeutics, Inc.

Contributing Author

Recent Articles by Fate Therapeutics, Inc.

May-30	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors FATE GlobeNewswire
May-28	Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress FATE GlobeNewswire
May-13	Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates FATE GlobeNewswire
May-02	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire